SG10201900628RA - Heterocyclic amides useful as protein modulators - Google Patents
Heterocyclic amides useful as protein modulatorsInfo
- Publication number
- SG10201900628RA SG10201900628RA SG10201900628RA SG10201900628RA SG10201900628RA SG 10201900628R A SG10201900628R A SG 10201900628RA SG 10201900628R A SG10201900628R A SG 10201900628RA SG 10201900628R A SG10201900628R A SG 10201900628RA SG 10201900628R A SG10201900628R A SG 10201900628RA
- Authority
- SG
- Singapore
- Prior art keywords
- protein modulators
- heterocyclic amides
- amides useful
- useful
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Peptides Or Proteins (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662319358P | 2016-04-07 | 2016-04-07 | |
| US201762461301P | 2017-02-21 | 2017-02-21 | |
| US201762461975P | 2017-02-22 | 2017-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201900628RA true SG10201900628RA (en) | 2019-02-27 |
Family
ID=58503675
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201900629VA SG10201900629VA (en) | 2016-04-07 | 2017-04-05 | Heterocyclic amides useful as protein modulators |
| SG10201900628RA SG10201900628RA (en) | 2016-04-07 | 2017-04-05 | Heterocyclic amides useful as protein modulators |
| SG11201808621TA SG11201808621TA (en) | 2016-04-07 | 2017-04-05 | Heterocyclic amides useful as protein modulators |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201900629VA SG10201900629VA (en) | 2016-04-07 | 2017-04-05 | Heterocyclic amides useful as protein modulators |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808621TA SG11201808621TA (en) | 2016-04-07 | 2017-04-05 | Heterocyclic amides useful as protein modulators |
Country Status (33)
Families Citing this family (126)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| EA034786B1 (ru) | 2015-08-13 | 2020-03-20 | Мерк Шарп И Доум Корп. | Циклические динуклеотидные соединения в качестве агонистов sting |
| NZ746112A (en) | 2016-03-18 | 2023-01-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| CN113549110B (zh) | 2016-04-07 | 2024-08-16 | 葛兰素史密斯克莱知识产权发展有限公司 | 用作蛋白质调节剂的杂环酰胺 |
| TN2020000158A1 (en) | 2016-10-04 | 2022-04-04 | Merck Sharp & Dohme | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| EP3604311A4 (en) | 2017-03-29 | 2021-01-13 | LegoChem Biosciences, Inc. | PYRROLOBENZODIAZEPINE DIMERIC PRECURSOR AND ASSOCIATED LIGAND-BOND CONJUGATE COMPOUND |
| SG11201908813QA (en) | 2017-04-13 | 2019-10-30 | Aduro Biotech Holdings Europe B V | Anti-sirp alpha antibodies |
| EP3621624B1 (en) | 2017-05-12 | 2023-08-30 | Merck Sharp & Dohme LLC | Cyclic di-nucleotide compounds as sting agonists |
| US11285131B2 (en) | 2017-08-04 | 2022-03-29 | Merck Sharp & Dohme Corp. | Benzo[b]thiophene STING agonists for cancer treatment |
| RU2020109328A (ru) | 2017-08-04 | 2021-09-06 | Мерк Шарп И Доум Корп. | Комбинации антагонистов pd-1 и бензо[b]тиофеновых агонистов sting для лечения рака |
| BR112020006780A2 (pt) * | 2017-10-05 | 2020-10-06 | Glaxosmithkline Intellectual Property Development Limited | moduladores do estimulador de genes do interferon (sting) |
| JP2020536106A (ja) * | 2017-10-05 | 2020-12-10 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｈｉｖの処置に有用なインターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質 |
| JP7262451B2 (ja) * | 2017-10-05 | 2023-04-21 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Ｓｔｉｎｇアゴニストの投与方法 |
| CN111566119A (zh) | 2017-11-10 | 2020-08-21 | 武田药品工业有限公司 | Sting调节剂化合物以及制备和使用方法 |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019125974A1 (en) | 2017-12-20 | 2019-06-27 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| CN110016025B (zh) * | 2018-01-08 | 2021-08-06 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2019134707A1 (zh) * | 2018-01-08 | 2019-07-11 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| CN112105357A (zh) * | 2018-02-16 | 2020-12-18 | Ucb生物制药有限责任公司 | 药用6,5杂双环衍生物 |
| US11311528B2 (en) | 2018-03-20 | 2022-04-26 | Merck Sharp & Dohme Corp. | Oxo-tetrahydro-isoquinoline carboxylic acids as STING inhibitors |
| EP3768310A1 (en) | 2018-03-23 | 2021-01-27 | Codiak BioSciences, Inc. | Extracellular vesicles comprising sting-agonist |
| WO2019195063A1 (en) | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Aza-benzothiophene compounds as sting agonists |
| WO2019195124A1 (en) | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Benzothiophenes and related compounds as sting agonists |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| ES2929415T3 (es) * | 2018-05-25 | 2022-11-29 | Incyte Corp | Compuestos heterocíclicos tricíclicos como activadores de STING |
| EP3813827A4 (en) | 2018-06-28 | 2022-04-13 | Jiangsu Hengrui Medicine Co., Ltd. | CONDENSED TRICYCLIC HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF |
| WO2020010451A1 (en) * | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| WO2020028565A1 (en) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Tricyclic heteraryl compounds as sting activators |
| WO2020028566A1 (en) * | 2018-07-31 | 2020-02-06 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| WO2020038387A1 (zh) | 2018-08-24 | 2020-02-27 | 杭州阿诺生物医药科技有限公司 | 高活性sting蛋白激动剂 |
| US12364702B2 (en) | 2018-08-29 | 2025-07-22 | Adlai Nortye Biopharma Co., Ltd. | Highly active sting protein agonist compound |
| KR102567590B1 (ko) | 2018-09-06 | 2023-08-17 | 다이이찌 산쿄 가부시키가이샤 | 신규 고리형 디뉴클레오티드 유도체 및 그 항체 약물 콘쥬게이트 |
| US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
| EP3890703B8 (en) | 2018-12-06 | 2023-10-11 | GlaxoSmithKline Intellectual Property Development Ltd | Novel pharmaceutical formulation comprising a sting modulator |
| EP3873896A4 (en) * | 2018-12-14 | 2022-08-31 | Jiangsu Hengrui Medicine Co., Ltd. | Tricyclic compounds as sting agonists, and preparation methods and medicinal uses thereof |
| WO2020132566A1 (en) * | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting pyrazole agonists and uses thereof |
| WO2020132582A1 (en) * | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting agonists and uses thereof |
| WO2020146237A1 (en) * | 2019-01-07 | 2020-07-16 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| WO2020151682A1 (zh) * | 2019-01-23 | 2020-07-30 | 成都先导药物开发股份有限公司 | 一种大环类免疫调节剂 |
| AU2020214477B2 (en) * | 2019-01-31 | 2022-10-27 | Hitgen Inc. | Immunomodulator |
| WO2020165600A1 (en) | 2019-02-14 | 2020-08-20 | Bicycletx Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
| AU2020231115B2 (en) | 2019-03-07 | 2025-02-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
| US20240108747A1 (en) | 2019-03-21 | 2024-04-04 | Lonza Sales Ag | Extracellular vesicle conjugates and uses thereof |
| SG11202109702QA (en) | 2019-03-21 | 2021-10-28 | Codiak Biosciences Inc | Extracellular vesicles for vaccine delivery |
| CA3132508A1 (en) * | 2019-03-28 | 2020-10-01 | Lupin Limited | Macrocyclic compounds as sting agonists |
| TW202104214A (zh) | 2019-04-05 | 2021-02-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 化合物 |
| WO2021000770A1 (zh) * | 2019-07-02 | 2021-01-07 | 凯复制药有限公司 | 可增强免疫活性的杂环化合物、其制备方法及其在医药上的应用 |
| US20230181758A1 (en) | 2019-07-03 | 2023-06-15 | Codiak Biosciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
| WO2021003445A1 (en) | 2019-07-03 | 2021-01-07 | Codiak Biosciences, Inc. | Extracellular vesicles targeting t cells and uses thereof |
| US11339159B2 (en) | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| PL4004002T3 (pl) * | 2019-07-22 | 2024-11-18 | Lupin Limited | Związki makrocykliczne jako agoniści sting i sposoby oraz ich zastosowania |
| CN112279835B (zh) * | 2019-07-24 | 2022-07-22 | 中国医学科学院药物研究所 | 芳环或芳杂环并咪唑类化合物，其制备方法及制药用途 |
| CN114174285B (zh) * | 2019-07-25 | 2023-10-31 | 上海济煜医药科技有限公司 | 杂环酰胺类化合物及其制备方法和应用 |
| TW202114710A (zh) | 2019-07-25 | 2021-04-16 | 英屬開曼群島商百濟神州有限公司 | 作為sting促效劑之環狀二核苷酸 |
| KR20220056176A (ko) * | 2019-08-02 | 2022-05-04 | 메르사나 테라퓨틱스, 인코포레이티드 | 암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물 |
| CN112521371B (zh) * | 2019-09-19 | 2022-11-25 | 中国药科大学 | 杂环酰胺类化合物、其可药用的盐及其制备方法和用途 |
| CN112521394A (zh) * | 2019-09-19 | 2021-03-19 | 中国药科大学 | 杂环酰胺类化合物、其可药用的盐及其制备方法和用途 |
| JP2022551420A (ja) | 2019-09-25 | 2022-12-09 | コディアック バイオサイエンシーズ， インコーポレイテッド | 腫瘍を治療するためのｉｌ－１２提示エクソソームとｓｔｉｎｇアゴニスト含有エクソソームとの併用 |
| EP4034081A1 (en) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Extracellular vesicle compositions |
| WO2021062290A1 (en) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Methods of producing extracellular vesicles |
| US20230241089A1 (en) | 2019-09-25 | 2023-08-03 | Codiak Biosciences, Inc. | Sting agonist comprising exosomes for treating neuroimmunological disorders |
| WO2021068866A1 (en) * | 2019-10-10 | 2021-04-15 | Beigene, Ltd. | Heterocyclic compounds as sting modulators |
| WO2021083383A1 (zh) * | 2019-11-02 | 2021-05-06 | 上海凌达生物医药有限公司 | 一类含氮稠环类sting调节剂类化合物、制备方法和用途 |
| CN112940004B (zh) * | 2019-12-11 | 2022-07-12 | 中国科学院上海药物研究所 | 一种杂环化合物及其用途 |
| CN114981265B (zh) * | 2019-12-18 | 2025-01-03 | Ctxt私人有限公司 | 化合物 |
| CN113087668B (zh) * | 2019-12-23 | 2022-11-04 | 中国科学院上海药物研究所 | 一类苯并咪唑二聚体、其制备方法及用途 |
| CN113248475B (zh) * | 2020-02-11 | 2023-03-17 | 中国科学院上海药物研究所 | 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途 |
| BR112022015283A2 (pt) | 2020-03-06 | 2022-09-20 | Daiichi Sankyo Co Ltd | Conjugado anticorpo-fármaco incluindo derivados de dinucleotídeos cíclicos |
| EP4117717A1 (en) | 2020-03-13 | 2023-01-18 | Codiak BioSciences, Inc. | Extracellular vesicles for treating neurological disorders |
| EP4121450A2 (en) | 2020-03-20 | 2023-01-25 | Codiak BioSciences, Inc. | Extracellular vesicles for therapy |
| MY210304A (en) | 2020-04-02 | 2025-09-10 | Mersana Therapeutics Inc | Antibody drug conjugates comprising sting agonists |
| TW202200136A (zh) | 2020-04-10 | 2022-01-01 | 日商小野藥品工業股份有限公司 | 癌治療方法 |
| WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
| KR20230061360A (ko) | 2020-09-02 | 2023-05-08 | 다이이찌 산쿄 가부시키가이샤 | 신규 엔도-β-N-아세틸글루코사미니다아제 |
| AU2021338438A1 (en) * | 2020-09-02 | 2023-03-23 | The Scripps Research Institute | Agonists of stimulator of interferon genes sting |
| EP4216993A2 (en) | 2020-09-23 | 2023-08-02 | Codiak BioSciences, Inc. | Methods of producing extracellular vesicles |
| WO2022066883A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Extracellular vesicles comprising kras antigens and uses thereof |
| EP4240488A1 (en) | 2020-11-09 | 2023-09-13 | Takeda Pharmaceutical Company Limited | Antibody drug conjugates |
| TW202246242A (zh) * | 2021-01-15 | 2022-12-01 | 美商西健公司 | 免疫調節抗體藥物結合物 |
| CN112920172B (zh) * | 2021-02-01 | 2022-03-22 | 厦门大学 | 一种干扰素刺激蛋白靶向化合物、其放射性标记物、及它们的制备方法与应用 |
| KR102881036B1 (ko) | 2021-02-17 | 2025-11-05 | 한국화학연구원 | 벤즈이미다졸 유도체를 유효 성분으로 포함하는 인터페론 유전자 자극제 조성물 |
| WO2022177307A1 (ko) * | 2021-02-17 | 2022-08-25 | 한국화학연구원 | 벤즈이미다졸 유도체를 유효 성분으로 포함하는 인터페론 유전자 자극제 조성물 |
| JP2024514707A (ja) | 2021-04-20 | 2024-04-02 | アンスティテュ・クリー | 免疫療法における使用のための組成物及び方法 |
| US20240285755A1 (en) | 2021-05-24 | 2024-08-29 | Glaxosmithkline Biologicals Sa | Adjuvants |
| WO2022246597A1 (en) * | 2021-05-24 | 2022-12-01 | Forever Millets Limited | Imidazopyridine derivatives as sting agonists |
| KR20240027018A (ko) * | 2021-06-25 | 2024-02-29 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | 비스-벤즈이미다졸 sting 효능제 면역접합체 및 이의 용도 |
| WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| CN115724838A (zh) * | 2021-08-26 | 2023-03-03 | 成都先导药物开发股份有限公司 | 一种适合作为抗体偶联药物效应分子的sting激动剂 |
| WO2023056468A1 (en) | 2021-09-30 | 2023-04-06 | Codiak Biosciences, Inc. | Extracellular vesicle comprising cholesterol tagged sting-agonist |
| EP4169513A1 (en) | 2021-10-19 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising sting agonists |
| CA3242000A1 (en) * | 2022-01-11 | 2023-07-20 | Jeongbeob Seo | Fused heteroaryl hydroxamates as sting agonists |
| AU2023215702A1 (en) * | 2022-02-02 | 2024-07-25 | F. Hoffmann-La Roche Ag | Imidazole macrocycles for the treatment of autoimmune disease |
| CN118742328A (zh) | 2022-02-22 | 2024-10-01 | 阿拉里斯生物技术股份公司 | 包含两个或更多个有效载荷的肽接头 |
| TW202346322A (zh) | 2022-03-02 | 2023-12-01 | 日商第一三共股份有限公司 | 含Ｆｃ分子之製造方法 |
| WO2024003773A1 (en) | 2022-07-01 | 2024-01-04 | Pfizer Inc. | 2,7-naphthyridine compounds as mastl inhibitors |
| CA3261000A1 (en) | 2022-07-05 | 2024-01-11 | Pfizer | PYRIDO[4,3-D]PYRIMIDINES COMPOUNDS |
| EP4582106A1 (en) | 2022-08-29 | 2025-07-09 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate including mutant fc region |
| AU2023356904A1 (en) * | 2022-10-03 | 2025-05-22 | Recombination Therapeutics, Llc | Pyrrolidine and imidazolidine based dna polymerase theta inhibitors and use thereof |
| WO2024074977A1 (en) | 2022-10-04 | 2024-04-11 | Pfizer Inc. | Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds |
| CN120379671A (zh) | 2022-10-18 | 2025-07-25 | 辉瑞公司 | 用于治疗癌症的化合物 |
| WO2024105563A1 (en) | 2022-11-16 | 2024-05-23 | Pfizer Inc. | Substituted bicyclic pyridone derivatives |
| WO2024137619A1 (en) | 2022-12-20 | 2024-06-27 | Bolt Biotherapeutics, Inc. | Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof |
| CN120981451A (zh) | 2023-02-27 | 2025-11-18 | 百欧恩泰欧洲股份公司 | 含有酰肼、肼和异羟肟酸官能团的sting激动剂 |
| WO2024180103A1 (en) | 2023-02-27 | 2024-09-06 | BioNTech SE | Sting agonists containing benzylic alcohol and benzylic amine functional groups |
| WO2024186626A1 (en) | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Aza-bicyclic sting agonist immunoconjugates, and uses thereof |
| AU2024253142A1 (en) | 2023-04-05 | 2025-10-16 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| WO2024213979A1 (en) | 2023-04-10 | 2024-10-17 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| WO2025012195A1 (en) * | 2023-07-10 | 2025-01-16 | F. Hoffmann-La Roche Ag | Bicyclic macrocycles for the treatment of autoimmune disease |
| WO2025029832A2 (en) * | 2023-07-31 | 2025-02-06 | Sutro Biopharma, Inc. | Sting agonist compounds and conjugates |
| WO2025057126A1 (ko) * | 2023-09-15 | 2025-03-20 | 삼진제약주식회사 | Sting(인터페론 유전자 자극인자) 활성화제로서의 헤테로 고리 유도체 및 이를 포함하는 약학적 조성물 |
| EP4534147A1 (en) | 2023-10-05 | 2025-04-09 | Sulis Therapeutics ApS | Sting antagonist compounds |
| WO2025094035A1 (en) | 2023-11-01 | 2025-05-08 | Pfizer Inc. | Toll-like receptor agonists and conjugates thereof |
| EP4663204A1 (en) | 2024-06-13 | 2025-12-17 | Sulis Therapeutics ApS | Compounds useful for the modulation of the activity of sting |
| EP4663632A1 (en) | 2024-06-13 | 2025-12-17 | Sulis Therapeutics ApS | Compounds useful for the modulation of the activity of sting |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| EP1065213A3 (en) | 1999-07-02 | 2003-11-05 | Japan Tobacco Inc. | HCV polymerase suitable for crystal structure analysis and method for using the enzyme |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| SK13752001A3 (sk) | 1999-12-27 | 2002-07-02 | Japan Tobacco, Inc. | Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv |
| NZ522755A (en) | 2000-05-19 | 2004-05-28 | Corixa Corp | Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds being administered in absence of exogenous antigen |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| CA2417806C (en) | 2000-08-04 | 2011-05-10 | Corixa Corporation | New immunoeffector compounds |
| US6310224B1 (en) | 2001-01-19 | 2001-10-30 | Arco Chemical Technology, L.P. | Epoxidation catalyst and process |
| HUP0400726A3 (en) | 2001-01-22 | 2007-05-29 | Merck & Co Inc | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| IL157940A0 (en) | 2001-03-19 | 2004-03-28 | Ono Pharmaceutical Co | Drugs containing triazaspiro [5.5] undecane derivatives as the active ingredient |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| CA2448737C (en) | 2001-07-20 | 2010-06-01 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| US6525028B1 (en) | 2002-02-04 | 2003-02-25 | Corixa Corporation | Immunoeffector compounds |
| US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
| IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
| EP1497469A4 (en) | 2002-04-04 | 2005-06-08 | Achillion Pharmaceuticals Inc | TEST FOR ASSESSING THE ACTIVITY OF COMPOUNDS AGAINST HCV USING A NOVEL DETECTION SYSTEM IN THE HCV REPLICIC |
| DOP2003000641A (es) | 2002-05-10 | 2003-11-15 | Pfizer | Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan |
| CA2489004C (en) | 2002-06-13 | 2013-01-08 | Crucell Holland B.V. | Agonistic binding molecules to the human ox40 receptor |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| WO2004037818A1 (en) | 2002-10-24 | 2004-05-06 | Glaxo Group Limited | 1-acyl-pyrrolidine derivatives for the treatment of viral infections |
| WO2004041201A2 (en) | 2002-11-01 | 2004-05-21 | Viropharma Incorporated | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
| ES2298627T3 (es) | 2002-12-13 | 2008-05-16 | Smithkline Beecham Corporation | Compuestos de ciclopropilo como antagonistas de ccr5. |
| CN1744899A (zh) | 2002-12-13 | 2006-03-08 | 史密丝克莱恩比彻姆公司 | 作为ccr5拮抗剂的哌啶衍生物 |
| AU2003300952A1 (en) | 2002-12-13 | 2004-07-09 | Smithkline Beecham Corporation | Indane compounds as ccr5 antagonists |
| DE60322423D1 (de) | 2002-12-13 | 2008-09-04 | Smithkline Beecham Corp | Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten |
| ES2312856T3 (es) | 2002-12-13 | 2009-03-01 | Smithkline Beecham Corporation | Compuestos heterociclicos como antagonistas de ccr5. |
| ES2311755T3 (es) | 2002-12-13 | 2009-02-16 | Smithkline Beecham Corporation | Compuestos de ciclohexilo como antagonistas de ccrs. |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
| US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| EP1591527B1 (en) | 2003-01-23 | 2015-08-26 | Ono Pharmaceutical Co., Ltd. | Substance specific to human pd-1 |
| US7148226B2 (en) | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| CN1829709A (zh) | 2003-08-01 | 2006-09-06 | 健亚生物科技公司 | 对抗黄病毒的双环咪唑衍生物 |
| WO2005014543A1 (ja) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用 |
| US20050176792A1 (en) | 2004-01-14 | 2005-08-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Ketone substituted benzimidazole compounds |
| JP2007518823A (ja) | 2004-01-23 | 2007-07-12 | アムゲン インコーポレイテッド | キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途 |
| IN2012DN04853A (enExample) | 2004-02-20 | 2015-09-25 | Boehringer Ingelheim Int | |
| CA2560058C (en) | 2004-03-15 | 2011-10-18 | David K.R. Karaolis | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| EP1748991A1 (en) | 2004-04-28 | 2007-02-07 | Arrow Therapeutics Limited | Morpholinylanilinoquinazo- line derivatives for use as antiviral agents |
| TW200600492A (en) | 2004-05-18 | 2006-01-01 | Achillion Pharmaceuticals Inc | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication |
| US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| CA2577525C (en) | 2004-08-18 | 2010-03-30 | Pfizer Inc. | Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same |
| GB0423673D0 (en) | 2004-10-25 | 2004-11-24 | Glaxo Group Ltd | Compounds |
| US20070060589A1 (en) * | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
| EP1879885A1 (en) | 2005-05-04 | 2008-01-23 | F. Hoffmann-Roche AG | Heterocyclic antiviral compounds |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR20080019213A (ko) | 2005-05-09 | 2008-03-03 | 아칠리온 파르마세우티칼스 인코포레이티드 | 티아졸 화합물 및 그 사용방법 |
| AU2006244068B9 (en) | 2005-05-10 | 2012-10-25 | Incyte Holdings Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| EP1782826A1 (en) | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions |
| US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| BRPI0811466A2 (pt) | 2007-05-07 | 2014-10-14 | Medimmune Llc | Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica. |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| SG186656A1 (en) | 2007-12-14 | 2013-01-30 | Bristol Myers Squibb Co | Binding molecules to the human ox40 receptor |
| EA019156B1 (ru) | 2008-02-01 | 2014-01-30 | Такеда Фармасьютикал Компани Лимитед | Производные оксима в качестве ингибиторов hsp90 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| WO2009143039A2 (en) | 2008-05-19 | 2009-11-26 | Schering Corporation | Heterocyclic compounds as factor ixa inhibitors |
| CA2735006A1 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
| ES2592216T3 (es) | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos |
| EP2358392B1 (en) | 2008-11-12 | 2019-01-09 | MedImmune, LLC | Antibody formulation |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| KR20110131312A (ko) | 2009-03-27 | 2011-12-06 | 프레시디오 파마슈티칼스, 인코포레이티드 | 융합된 고리 ｃ형 간염 억제제 |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2011091446A1 (en) | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Chemical compounds |
| UY33288A (es) * | 2010-03-25 | 2011-10-31 | Glaxosmithkline Llc | Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico |
| US8598156B2 (en) * | 2010-03-25 | 2013-12-03 | Glaxosmithkline Llc | Chemical compounds |
| US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
| ES2715611T3 (es) * | 2010-05-17 | 2019-06-05 | Incozen Therapeutics Pvt Ltd | Compuestos novedosos de 3H-imidazo[4,5-b]piridina-3,5-disustituida y 3H-[1,2,3]triazolo[4,5-b]piridina 3,5-disustituida como moduladores de proteína cinasas |
| CN101898945B (zh) | 2010-07-27 | 2013-05-08 | 大连理工大学 | 盐析萃取发酵液中丙酮和丁醇的方法 |
| EA029793B1 (ru) | 2010-08-23 | 2018-05-31 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Антитела к ох40 и способы их применения |
| WO2012083053A2 (en) * | 2010-12-15 | 2012-06-21 | Abbott Laboratories | Anti-viral compounds |
| CN106749662B (zh) | 2011-03-31 | 2021-06-18 | 国家医疗保健研究所 | 抗icos的抗体及其用途 |
| AR087405A1 (es) | 2011-08-01 | 2014-03-19 | Genentech Inc | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek |
| CA2845810C (en) | 2011-08-23 | 2017-03-28 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| EP2844756A4 (en) | 2012-04-30 | 2016-02-24 | Glen N Barber | MODULATION OF IMMUNE REACTIONS |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| AU2013271375B2 (en) | 2012-06-08 | 2018-03-22 | Aduro Biotech, Inc. | Compositions and methods for cancer immunotherapy |
| IN2014MN02562A (enExample) * | 2012-06-27 | 2015-07-24 | 4Sc Discovery Gmbh | |
| ES2684552T3 (es) | 2012-09-03 | 2018-10-03 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos dirigidos contra ICOS para tratar la enfermedad de injerto contra hospedador |
| JP6461800B2 (ja) | 2012-10-04 | 2019-01-30 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ヒトモノクローナル抗ｐｄ−ｌ１抗体および使用方法 |
| AU2013358892B2 (en) | 2012-12-13 | 2018-06-21 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| PE20160080A1 (es) | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| EP3071209A4 (en) | 2013-11-19 | 2017-08-16 | The University of Chicago | Use of sting agonist as cancer treatment |
| JP6442534B2 (ja) | 2014-06-02 | 2018-12-19 | ベース４ イノベーション リミテッド | ヌクレオチド多型の検出方法 |
| JP6462006B2 (ja) * | 2014-06-04 | 2019-01-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｓｔｉｎｇのモジュレーターとしての環式ジヌクレオチド |
| EP3309174B1 (en) | 2014-07-11 | 2022-05-11 | Ventana Medical Systems, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| RS60614B1 (sr) | 2015-03-23 | 2020-08-31 | Jounce Therapeutics Inc | Antitela za icos |
| EA034786B1 (ru) | 2015-08-13 | 2020-03-20 | Мерк Шарп И Доум Корп. | Циклические динуклеотидные соединения в качестве агонистов sting |
| RU2020113165A (ru) | 2015-12-03 | 2020-06-09 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Циклические пуриновые динуклеотиды в качестве модуляторов sting |
| JP2019510802A (ja) | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | タンパク質調節物質として有用な複素環アミド |
| CN113549110B (zh) * | 2016-04-07 | 2024-08-16 | 葛兰素史密斯克莱知识产权发展有限公司 | 用作蛋白质调节剂的杂环酰胺 |
-
2017
- 2017-04-05 CN CN202110799242.1A patent/CN113549110B/zh active Active
- 2017-04-05 AU AU2017247798A patent/AU2017247798C1/en active Active
- 2017-04-05 SG SG10201900629VA patent/SG10201900629VA/en unknown
- 2017-04-05 CR CR20200044A patent/CR20200044A/es unknown
- 2017-04-05 MX MX2020009947A patent/MX387354B/es unknown
- 2017-04-05 KR KR1020187031915A patent/KR102527786B1/ko active Active
- 2017-04-05 MY MYPI2018703686A patent/MY189100A/en unknown
- 2017-04-05 ES ES17716312T patent/ES2921855T3/es active Active
- 2017-04-05 US US16/091,189 patent/US10981901B1/en active Active
- 2017-04-05 PL PL17716312.8T patent/PL3440076T3/pl unknown
- 2017-04-05 EP EP17716312.8A patent/EP3440076B1/en active Active
- 2017-04-05 MX MX2020009948A patent/MX387353B/es unknown
- 2017-04-05 SG SG10201900628RA patent/SG10201900628RA/en unknown
- 2017-04-05 PT PT177163128T patent/PT3440076T/pt unknown
- 2017-04-05 PE PE2018001834A patent/PE20181884A1/es unknown
- 2017-04-05 JO JOP/2017/0083A patent/JOP20170083B1/ar active
- 2017-04-05 NZ NZ745957A patent/NZ745957A/en unknown
- 2017-04-05 RS RS20220734A patent/RS63462B1/sr unknown
- 2017-04-05 UY UY0001037195A patent/UY37195A/es unknown
- 2017-04-05 PE PE2018002322A patent/PE20181920A1/es unknown
- 2017-04-05 CN CN201780022379.8A patent/CN109071514B/zh active Active
- 2017-04-05 SG SG11201808621TA patent/SG11201808621TA/en unknown
- 2017-04-05 LT LTEPPCT/IB2017/051945T patent/LT3440076T/lt unknown
- 2017-04-05 MX MX2018012333A patent/MX379169B/es unknown
- 2017-04-05 CN CN201811311714.9A patent/CN109608443B/zh active Active
- 2017-04-05 UA UAA201810983A patent/UA123407C2/uk unknown
- 2017-04-05 SM SM20220339T patent/SMT202200339T1/it unknown
- 2017-04-05 EP EP22159533.3A patent/EP4032885A1/en active Pending
- 2017-04-05 DK DK17716312.8T patent/DK3440076T3/da active
- 2017-04-05 JP JP2018552758A patent/JP6746712B2/ja active Active
- 2017-04-05 CR CR20200045A patent/CR20200045A/es unknown
- 2017-04-05 SI SI201731184T patent/SI3440076T1/sl unknown
- 2017-04-05 KR KR1020187032396A patent/KR102527784B1/ko active Active
- 2017-04-05 IL IL285702A patent/IL285702B/en unknown
- 2017-04-05 WO PCT/IB2017/051945 patent/WO2017175147A1/en not_active Ceased
- 2017-04-05 CA CA3019630A patent/CA3019630A1/en active Pending
- 2017-04-05 HU HUE17716312A patent/HUE058932T2/hu unknown
- 2017-04-05 PE PE2018002003A patent/PE20181919A1/es unknown
- 2017-04-05 HR HRP20220936TT patent/HRP20220936T1/hr unknown
- 2017-04-06 TW TW106111324A patent/TWI776806B/zh active
- 2017-04-06 TW TW111130004A patent/TWI868471B/zh active
- 2017-04-06 TW TW107147613A patent/TWI777014B/zh active
-
2018
- 2018-01-03 US US15/730,664 patent/US10189820B2/en active Active
- 2018-08-30 IL IL261482A patent/IL261482B/en unknown
- 2018-09-06 IL IL261657A patent/IL261657B/en unknown
- 2018-09-13 AU AU2018229498A patent/AU2018229498C1/en active Active
- 2018-09-13 AU AU2018229497A patent/AU2018229497C1/en active Active
- 2018-10-04 DO DO2018000217A patent/DOP2018000217A/es unknown
- 2018-10-04 CO CONC2018/0010727A patent/CO2018010727A2/es unknown
- 2018-10-05 PH PH12018502151A patent/PH12018502151B1/en unknown
- 2018-10-05 CL CL2018002850A patent/CL2018002850A1/es unknown
- 2018-10-11 PH PH12018502179A patent/PH12018502179A1/en unknown
- 2018-10-15 PH PH12018502202A patent/PH12018502202A1/en unknown
- 2018-11-20 CL CL2018003291A patent/CL2018003291A1/es unknown
- 2018-11-20 CL CL2018003290A patent/CL2018003290A1/es unknown
-
2020
- 2020-01-30 DO DO2020000018A patent/DOP2020000018A/es unknown
- 2020-01-30 AU AU2020200692A patent/AU2020200692C1/en active Active
- 2020-01-30 DO DO2020000019A patent/DOP2020000019A/es unknown
- 2020-02-26 JP JP2020030908A patent/JP6861307B2/ja active Active
-
2021
- 2021-01-25 US US17/156,893 patent/US11365190B2/en active Active
- 2021-03-26 JP JP2021054203A patent/JP7119158B2/ja active Active
-
2022
- 2022-05-17 US US17/663,749 patent/US11970480B2/en active Active
- 2022-08-01 JP JP2022122895A patent/JP7466596B2/ja active Active
- 2022-08-15 IL IL295649A patent/IL295649B2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502202A1 (en) | Heterocyclic amides useful as protein modulators | |
| PH12018502136A1 (en) | Heterocyclic amides useful as protein modulators | |
| SG10201909485YA (en) | Bicyclic quinazolinone derivatives | |
| PH12017500095A1 (en) | Imidazopyridazine compounds | |
| MX2016015247A (es) | Derivados de benceno-sulfonamida y su uso como moduladores del receptor c huerfano relacionado a acido retinoico (rorc). | |
| MX2015006926A (es) | Derivados de bencil sulfonamida como moduladores del receptor huerfano relacionado con el receptor retinoide (rorc). | |
| PH12020550905A1 (en) | Process for preparing antihelmintic 4-amino-quinoline-3-carboxamide derivatives | |
| MX2017005158A (es) | Derivado heterociclico que tiene actividad de activacion de proteina cinasa activada por adenosina monofostato (ampk). | |
| MX2016005128A (es) | Derivados de 5,6,7,8-tetahidro-5,8-metanocinolina como moduladores del receptor huerfano y relacionado con acido retinoico (rorc) para el tratamiento de enfermedades autoinmunes. | |
| MX2016008499A (es) | Derivados de arilsultamo como moduladores del receptor huerfano relacionado con el receptor de retinoide (rorc). | |
| MX2017002775A (es) | Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b. | |
| MX379245B (es) | Compuesto de tres ciclos y aplicaciones del mismo | |
| MX2015015614A (es) | Derivados de aril sultama como moduladores del receptor huerfano relacionado con el receptor del retinoide (rorc). | |
| PH12017501955A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease | |
| HK1258966A1 (zh) | 作为rorc调节剂的苄基磺酰胺衍生物 | |
| EA201892425A1 (ru) | Гетероциклические амиды, пригодные в качестве модуляторов белков | |
| WO2016073652A8 (en) | Iminosugars useful for the treatment of viral diseases | |
| MX2021010016A (es) | Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfon il-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-m etilbenzoil)guanidina. | |
| EA201991141A1 (ru) | Усилители bmp | |
| TN2016000549A1 (en) | Novel polymorphic form of n-[2-(6-fluoro-1h-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer's | |
| MA44606B1 (fr) | Amides hétérocycliques utiles en tant que modulateurs de protéine |